Conference report: Phase 3 SUSTAIN FORTE trial of investigational 2mg dose of semaglutide injection demonstrates superior reductions in blood sugar vs 1mg in adults with type 2 diabetes
RCT (n=961) met primary endpoint, where people on once-weekly semaglutide 2mg (as an add-on to metformin with/without sulfonylureas) with elevated mean baseline HbA1C of 8.9% demonstrated statistically significant 2.2% reduction in HbA1C vs. 1.9% with 1 mg after 40 weeks.
Source:
Biospace Inc.
SPS commentary:
On the basis of the primary results, Novo Nordisk previously announced the submission of a label extension application to the European Medicines Agency in December 2020, and to the FDA in May 2021, for an additional higher dose of 2mg for adults with type 2 diabetes.